Procter & Gamble remains focused on conventional retail sales, though it will continue to leverage the DTC distribution channel for several categories, CFO Jon Moeller says. Health care sales in the firm's latest quarter jumped 7%, outperforming other sectors.
Building online sales through P&G Shop and websites for brands including Crest oral care is not a sign that Procter & Gamble Co.expects to make a “mass move” to direct or subscription sales for its consumer care products, says Chief Financial Officer Jon Moeller.
Even as it enters the subscription-distribution space with men's grooming products and as market analysts hail a promising future for...
Revised recommendation is based on most recent data on circulating strains in US, where KP.3 is now dominant. Novavax sticks with plans targeting the JN.1 ‘parent strain.’
With the deadline for comments on the US FDA’s draft guidance less than a month away, the Pink Sheet offers an infographic outlining what the agency is expecting in diversity action plans and when that might be implemented.
Cardiovascular and Renal Drugs Advisory Committee will consider whether open-label extension data from a randomized trial that failed its primary endpoint, along with a historical control comparison, are enough to support approval in the ultra-rare disease.
Recent ODAC meetings suggest the FDA will expand focus beyond applications with pending approval decisions to refining trial designs and drug labels for competitors.
Cardiovascular and Renal Drugs Advisory Committee will consider whether open-label extension data from a randomized trial that failed its primary endpoint, along with a historical control comparison, are enough to support approval in the ultra-rare disease.
Recent ODAC meetings suggest the FDA will expand focus beyond applications with pending approval decisions to refining trial designs and drug labels for competitors.
The agency also should explain the potential consequences for sponsors if enrollment goals are not met, stakeholders say in comments on the DAP draft guidance. Some commenters urged the FDA to apply waiver criteria flexibly, especially for rare diseases.
